NCT03091192 2026-01-23Savolitinib vs. Sunitinib in MET-driven PRCC.AstraZenecaPhase 3 Active not recruiting60 enrolled 15 charts
NCT04225299 2020-11-13Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate CancerSteba Biotech S.A.Phase 3 Withdrawn
NCT00838201 2018-10-18Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate CancerAmgenPhase 3 Completed384 enrolled 8 charts